Number 5: Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory bowel disease (IBD) among children and young adults. Number 4: About 13% ...

Explore the latest advancements in rheumatology biosimilars, including FDA approvals, patient switching trends, and ...

Biosimilar SB12 or Epysqli (eculizumab-aagh; Samsung Bioepis) is equivalent to reference eculizumab (Soliris) for treating complement inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria ...

Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory bowel ...

Josh Canavan, PharmD, head of pharmacy at RazorMetrics, and Chris O'Dell, senior vice president of market solutions at Turquoise Health, discuss how the health care system must overcome patient ...

Number 5: Explore how real-world evidence and biosimilars enhance insulin access and adherence, improving diabetes care and outcomes for patients who have type 2 diabetes. Number 4: The new data were ...

While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more ...